PCSK9 and peripheral arterial disease: According to the ESC 2019 guidelines, patients with PAD should be treated with a lipid-lowering therapy with a maximum tolerated dose of statin plus ezetimibe or a combination with a PCSK9 inhibitor (if needed) to reduce the risk of ASCVD events.